Alps Advisors Inc Vaxcyte, Inc. Transaction History

Alps Advisors Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$59.79 - $81.05 $658,945 - $893,252	11,021 Added 16.88%	76,316 $5.21 Million
Q4 2023 Feb 14, 2024	SELL	$45.35 - $63.41 $181,853 - $254,274	-4,010 Reduced 5.79%	65,295 $4.1 Million
Q3 2023 Nov 14, 2023	BUY	$46.0 - $53.1 $19,596 - $22,620	426 Added 0.62%	69,305 $3.53 Million
Q2 2023 Aug 14, 2023	BUY	$34.66 - $54.07 $559,862 - $873,392	16,153 Added 30.64%	68,879 $3.44 Million
Q1 2023 May 10, 2023	SELL	$36.27 - $47.2 $31,953 - $41,583	-881 Reduced 1.64%	52,726 $1.98 Million
Q4 2022 Feb 14, 2023	BUY	$20.58 - $47.95 $436,213 - $1.02 Million	21,196 Added 65.4%	53,607 $2.57 Million
Q3 2022 Nov 14, 2022	SELL	$21.69 - $28.53 $47,370 - $62,309	-2,184 Reduced 6.31%	32,411 $778,000
Q2 2022 Aug 11, 2022	BUY	$17.68 - $26.58 $611,639 - $919,535	34,595 New	34,595 $753,000

357

123M

775K

433K

Ticker PCVX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,315,100
Market Cap $5.45B
Description
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

Stay updated on Alps Advisors Inc with notifications on news.